Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Exogenous surfactant in acute respiratory distress syndrome: more is better

A. Anzueto
European Respiratory Journal 2002 19: 787-789; DOI: 10.1183/09031936.02.00284902
A. Anzueto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Pulmonary surfactant is a complex of highly active phospholipids and proteins that cover the alveolar epithelial surface of the lungs 1. Surfactant is synthesized in the alveolar type-II cells, stored in the lamellar bodies, and secreted to the alveolar space where it undergoes complex changes 2. The composition of lung surfactant in humans is very constant, although it may change in disease states 3. Phospholipids account for 85% of its composition and the main component is dipalmitoylphosphatidylcholine (DPPC). In addition, surfactant contains different apoproteins, neutral lipids, and carbohydrates 4.

Pulmonary-surfactant dysfunction can lead to acute lung injury and is characterized by alveolar instability, floating, and collapse. These abnormalities have been shown to occur in acute respiratory distress syndrome (ARDS) 5, 6 and infant respiratory distress syndrome (IRDS) 7. Since the initial report of ARDS by Ashbaugh et al. 5, abnormalities of the surfactant system have been recognized. Petty and co-workers 8, 9, later reported both qualitative and quantitative abnormalities in the surfactant content of ARDS patients. It is now known that surfactant dysfunction plays a major role in the pathophysiology of ARDS 6, 10, and functional changes have been described not only in patients with established ARDS, but also in patients at risk 10–12. The main biochemical abnormalities include an 80% fall in the total phospholipid content, decline in the fractional content of DPPC and phosphatidylglycerol and other fractions, and loss of apoproteins (90% of surfactant protein (SP)-A and SP-B) 6, 7. This loss of alveolar surfactant is due to several factors including the presence of plasma proteins 13, cleavage of phospholipids by serum phospholipases 14, formation of free radical species (including nitrates, lipid peroxidation, etc.) 15–17, and conversion to nonfunctional surfactant with more phospholipid aggregates 14.

Exogenous-surfactant replacement has been successfully achieved in IRDS 7, but clinical trials in ARDS have had mixed results. Initial preliminary reports, mainly phase-II multicentre trials, have shown that exogenous artificial surfactant (Exosurf®) 18 or bovine surfactant (Survanta®) 19 in ARDS can improve oxygenation and lung mechanics. The authors' group reported the results of a large, randomized, multicentre, prospective trial involving 725 patients in sepsis-induced ARDS treated with Exosurf® or placebo 20. This study did not show any improvement in either oxygenation and/or survival benefit of exogenous-surfactant supplementation.

There have been several speculations as to why the Exosurf® trial failed to show any improvement in the physiological parameters and/or survival in patients with ARDS. One explanation could be related to the underlying condition that resulted in ARDS. In the study by Gregory et al. 19, patients had several precipitating aetiologies to ARDS whereas the Exosurf® study was limited to sepsis-induced ARDS. Thus, the aetiology of ARDS may have to be taken into consideration when future studies are designed.

Another potential explanation for the difference in the results, could be related to the surfactant preparation that was utilized. Exosurf® is an exogenous surfactant that does not contain apoproteins and this can affect the onset of action and be inhibited by serum proteins. The study by Gregory et al. 19 used a bovine surfactant that contains two apoprotein constituents, whereas the synthetic preparation contains neither protein nor peptides and needs to achieve an in vitro critical concentration in order to exert its effects 16. These data suggest that for an exogenous surfactant preparation to be effective, it must contain apoproteins.

Finally, the mode of delivery of surfactant may be crucial. In the Exosurf® trial 20, surfactant was delivered by continuous aerosolization, but MacIntyre et al. 21, showed that only 4.5% of aerosolized radiolabelled surfactant reached the lungs thus, >5 µg of 102 µg of aerosolized DPPC·kg−1·day−1 actually reached the lungs in this study. It is also possible that the small amount of delivered surfactant was inhibited by the same inflammatory mediators associated with ARDS, and therefore had no effect.

In this issue of the European Resipratory Journal, Günther et al. 22 reported on the results of 27 patients with ARDS who received 300 mg·kg−1 of body weight of natural bovine surfactant extract (Alveofact®) delivered to each segment of the lung via a fibreoptic bronchoscope. This study showed that using the bronchoscope to deliver surfactant had no deleterious effects on gas exchange, lung mechanics, or haemodynamics. These patients had a significant improvement in oxygenation within 12 h, although it should be noted that in seven patients in whom the gas exchange deteriorated; additional surfactant was administered within the first 24 h. There was a significant decrease in mortality in the study patients, 44% compared to the calculated mortality of 74%. This study further supports the concept that larger volumes of surfactant need to be delivered to these patients in order to have a physiological effect. This investigation has provided several important contributions to the literature. First, the optimal surfactant preparation is very important and should contain apoproteins. Second, in order to achieve a physiological response, surfactant must be administered in large volumes into the adult lungs.

Other investigators have suggested that bronchoscopic instillation of surfactant not only results in delivery of large volumes of the material, but also allows the clinician to perform a bronchoalveolar lavage in order to remove inflammatory mediators. Wiswell et al. 23 used a human recombinant protein-B surfactant preparation that was delivered to each bronchopulmonary segment. In this study, the material was suctioned in an effort to remove at least 50% of the volume instilled. These investigators showed that the fluid removed contained large amounts of inflammatory mediators.

The question that needs to be answered is, what happens to the exogenous surfactant once it is delivered into injured lungs? The manuscript by Walmrath et al. 24 in this issue of the European Respiratory Journal, reported the impact of exogenous surfactant administration on the biochemical and biophysical properties in patients with severe ARDS and septic shock. These investigators obtained bronchoalveolar lavage samples 3 h prior to, and 15–18 and 72 h after exogenous surfactant administration. Prior to surfactant administration, these patients had a massive alveolar protein load, a reduced percentage of large surfactant aggregates, a loss of phosphatidylcholine, a significant reduction of apoproteins (SP-A, SP-B and SP-C), as well as a reduction in surfactant functional activity. Surfactant administration resulted in a marked increase in the phospholipid pool, but the large alveolar protein load was still present. The surface tension lowering properties were markedly improved, but not fully recovered. These samples also showed a significant effect on the biochemical and functional properties of endogenous surfactant. Therefore, the bronchoscopic administration of surfactant resulted in an improvement of some of the biochemical and biophysical characteristics of surfactant in patients with ARDS.

What are the lessons of these studies for clinicians? Exogenous-surfactant administration in acute respiratory distress syndrome can significantly improve oxygenation and survival, but must be administered in large volumes. Direct bronchoscopic instillation may be one way to achieve these effects. Although surfactant preparations are not approved by the Federal Drug Administration for use in patients with acute respiratory distress syndrome, these data show promise that it may be an important adjunctive therapy in patients with acute respiratory distress syndrome and refractory hypoxaemia.

    • © ERS Journals Ltd

    References

    1. ↵
      King RJ, Clements JA. Surface active materials from dog lung: composition and physiological correlations. Am J Physiol 1972;223:715–725.
      OpenUrlFREE Full Text
    2. ↵
      Gross NK, Barnes E, Narine KR. Recycling of surfactant in black and beige mice: pool sizes and kinetics. J Appl Physiol 1988;64:1027–1025.
      OpenUrlCrossRef
    3. ↵
      Hallman M, Spragg RG, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure: study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982;70:673–683.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Jobe A, Ikegami M. State of the art: surfactant for the treatment of respiratory distress syndrome. Am Rev Respir Dis 1987;136:1256–1275.
      OpenUrlPubMedWeb of Science
    5. ↵
      Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;2:319–323.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993;147:218–233.
      OpenUrlCrossRefPubMedWeb of Science
    7. ↵
      Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959;97:571–573.
      OpenUrl
    8. ↵
      Petty TL, Reiss OK, Paul GW, Silvers GW, Elkins ND. Characteristics of pulmonary surfactant in adult respiratory syndrome associated with trauma and shock. Am Rev Respir Dis 1977;115:531–536.
      OpenUrlPubMedWeb of Science
    9. ↵
      Petty TL, Silvers GW, Paul GW, Stanford RE. Abnormalities in lung properties and surfactant function in adult respiratory distress syndrome. Chest 1979;75:571–574.
      OpenUrlCrossRefPubMedWeb of Science
    10. ↵
      Gregory TJ, Longmore WJ, Moxley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991;88:1976–1981.
      OpenUrlCrossRefPubMedWeb of Science
    11. Seeger W, Pison U, Büchhorn T, et al. Alterations in alveolar surfactant following severe multiple trauma In: von Wichert P, Muller B, editors. Progress in Respiration Research, vol. 25 Basic Research on Lung SurfactantBasel, Karger, pp. 215–223.
    12. ↵
      Günther A, Meier U, Schmidt R, et al. Alteration of surfactant fatty acid profile in acute inflammatory and chronic interstitial lung disease. Am J Respir Crit Care Med 1994;151:A76.
      OpenUrl
    13. ↵
      Holm BA, Enhorning G, Notter RH. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity. Chem Phys Lipids 1988;49:49–55.
      OpenUrlCrossRefPubMedWeb of Science
    14. ↵
      Holm BA, Keicher L, Lui MY, Sokolowskim J, Enhorning JG. Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol 1991;71:317–321.
      OpenUrlAbstract/FREE Full Text
    15. ↵
      Cifuentes J, Ruiz-Oronoz J, Myles C, Nives B, Carlo WA, Matalon S. Interaction of surfacant mixtures with reactive oxygen and nitrogen species. J Appl Physiol 1995;78:1800–1805.
      OpenUrlAbstract/FREE Full Text
    16. ↵
      Gilliard N, Heldt GP, Loredo J, et al. Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters tension properties. J Clin Invest 1994;93:2608–2615.
      OpenUrlPubMedWeb of Science
    17. ↵
      Veldhuizen RA, McCaigh LA, Akino T, Lewis JF. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995;152:1867–1871.
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      Wiedemann H, Baughman R, de Boisblanc B, et al. A multi centered trial in human sepsis-induced ARDS of an aerosolized synthetic surfactant (Exosurf). Am Rev Respir Dis 1992;145:A184.
      OpenUrl
    19. ↵
      Gregory TJ, Steinberg KP, Spragg R, Gadek JE. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;155:1309–1315.
      OpenUrlPubMedWeb of Science
    20. ↵
      Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996;334:1417–1421.
      OpenUrlCrossRefPubMedWeb of Science
    21. ↵
      MacIntyre NR, Coleman RE, Schuller FS, Zaccardelli D, Pattishall EN. Efficiency of the delivery of aerosolized artificial surfactant in intubated patients with the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994;149:A125.
      OpenUrl
    22. ↵
      Günther A, Schmidt R, Harodt J, et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J 2002;19:797–804.
      OpenUrlAbstract/FREE Full Text
    23. ↵
      Wiswell TE, Smith RM, Katz LB, et al. Bronchopulmonary segmental lavage with surfaxin (KL4-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 1999;160:1188–1195.
      OpenUrlPubMedWeb of Science
    24. ↵
      Walmrath D, Grimminger F, Pappert D, et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J 2002;19:805–810.
      OpenUrlAbstract/FREE Full Text
    PreviousNext
    Back to top
    View this article with LENS
    Vol 19 Issue 5 Table of Contents
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Exogenous surfactant in acute respiratory distress syndrome: more is better
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    Exogenous surfactant in acute respiratory distress syndrome: more is better
    A. Anzueto
    European Respiratory Journal May 2002, 19 (5) 787-789; DOI: 10.1183/09031936.02.00284902

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Exogenous surfactant in acute respiratory distress syndrome: more is better
    A. Anzueto
    European Respiratory Journal May 2002, 19 (5) 787-789; DOI: 10.1183/09031936.02.00284902
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • New definitions of pre-extensively and extensively drug resistant TB
    • Utilising biomarkers to predict right heart maladaptive phenotype
    • The PELICAN ERS Clinical Research Collaboration
    Show more Editorials

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • CME
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Submit a manuscript
    • ERS author centre

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2021 by the European Respiratory Society